Revocon Tablet (Tetrabenazine 25mg)

What is Revocon Tablet (Tetrabenazine 25mg)?

Revocon is an oral prescription tablet containing 25 mg of tetrabenazine, a selective VMAT2 inhibitor that reduces presynaptic dopamine release in the central nervous system. It is primarily prescribed to manage chorea — the rapid, involuntary, jerking movements that disrupt daily life in people living with Huntington's disease — and is also used clinically for certain hyperkinetic movement disorders such as tardive dyskinesia.

Key features

• Active ingredient — each tablet delivers 25 mg of tetrabenazine, a well-established monoamine-depleting agent.
• Targeted mechanism — selectively inhibits vesicular monoamine transporter type 2 (VMAT2), lowering dopamine signaling linked to involuntary movement.
• Movement-disorder indication — formulated specifically for chorea associated with Huntington's disease and similar hyperkinetic conditions.
• Scored oral tablet — the 25 mg strength allows flexible titration in small increments, an important factor when starting therapy or adjusting dose over time.
• Prescription-only supply — dispensed under medical supervision, so dosing can be matched to symptom severity and tolerability.
• Convenient daily dosing — taken orally with water, typically in divided doses throughout the day per the prescribing clinician's instructions.
• Supplied by HealthyRXS — listed under SKU 3850 with order quantities and pricing tailored to longer treatment courses.

Who is Revocon Tablet (Tetrabenazine 25mg) for?

This medication is intended for adults who have been formally diagnosed with Huntington's disease chorea or another movement disorder for which a neurologist or movement-disorder specialist has prescribed tetrabenazine. It is not a self-care product — it requires baseline assessment, dose titration, and ongoing monitoring for side effects such as sedation, depression, parkinsonism, and orthostatic changes. Patients and caregivers managing a long-term treatment plan at home, with regular clinical follow-up, are the typical users.

How does Revocon Tablet (Tetrabenazine 25mg) compare?

Compared with older, broad-acting dopamine-receptor blockers such as typical antipsychotics, tetrabenazine works upstream by depleting monoamine storage rather than blocking receptors, which generally avoids the long-term receptor-related risks that gave those drugs their reputation. Against newer VMAT2 inhibitors marketed for tardive dyskinesia, the 25 mg tetrabenazine tablet offers a longer clinical track record and more granular dose adjustment, though it usually requires multiple daily doses and closer monitoring for mood-related effects. For shoppers filling an existing prescription, it represents an established, titratable option within the VMAT2-inhibitor category.